The Business ReportTargacept's Lead Compound Ties PlaceboNovember 11, 2011 | David FordTargacept, with over 140 employees is the Piedmont Triad Research Park’s flagship biotech company. CEO, Don deBethizy spun the drug-discovery company out of R.J. Reynolds Tobacco Co. 11 years ago, and it’s been growing steadily ever since.
Targacept has an enormous pipeline of new drugs at various stages of completion that deal with brain disorders from Alzheimer’s to Parkinson’s. One of them is the company's lead compound, an antidepressant named TC-5214—its first to reach the final stage of clinical trials. On Tuesday, while still in that stage, 5214 met with a major set back.
Last week Business Journal Contributing Writer and Director of the Journalism Program at Wake Forest University Justin Catanoso spoke with deBethizy about the challenges and promise of bringing a new drug to market. Justin shared that conversation with WFDD’s David Ford. Full archive of The Business Report >>
|
WFDD News Archives
-
November 1, 2011: Hearing sought in Duke, Progress Energy merger (Keri Brown)
-
November 1, 2011: Lights, Camera, Action Come to Graham
(Keri Brown)
-
October 28, 2011: Business contest hope to inspire Triad-Piedmont entrepreneurs (Keri Brown)
-
October 28, 2011: Triad residents voice concerns at public hearing on proposed utility rate increases (Keri Brown)
-
October 28, 2011: Taking PART in Ride Sharing (David Ford)
-
October 27, 2011: Former UNCSA Chancellor Gets National Opera Award (David Ford)
-
October 26, 2011: High Point market furniture show sees strong showing (Keri Brown)
|
|
| Su |
M |
T |
W |
Th |
F |
Sa | | | | | 1 | 2 | 3 | 4 | | 5 | 6 | 7 | 8 | 9 | 10 | 11 | | 12 | 13 | 14 | 15 | 16 | 17 | 18 | | 19 | 20 | 21 | 22 | 23 | 24 | 25 | | 26 | 27 | 28 | 29 | 30 | 31 | |
|
